Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUDSON umbrella study in NSCLC patients progressed on anti-PD-1/PD-L1 therapy
2017-002208-28Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Nov 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab, ceralasertib and trastuzumab deruxtecan in non-small cell lung cancer (NSCLC) (4 arms), sponsored by AstraZeneca. Primary endpoint: Objective response rate (ORR). Started Nov 2017; status: active.
02
Drugs
durvalumabceralasertibtrastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-002208-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002208-28.